Nan Zhang1, Changjuan Wei, Hongjian Du, Fu-Dong Shi, Yan Cheng. 1. Department of Neurology, Key Laboratory of Post-Traumatic Neuro-Repair and Regeneration in the Central Nervous System, Ministry of Education, Tianjin Key Laboratory of Injuries, Variations and Regeneration of the Nervous System, and Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China.
Abstract
BACKGROUND/AIMS: Memantine has been approved by the Food and Drug Administration for the treatment of moderate-to-severe Alzheimer's disease (AD). However, the effect of memantine on patients with mild-to-moderate AD is unclear. METHODS: This study is a post hoc analysis of a double-blind clinical trial. Donepezil was used as the standard control treatment. Outcomes included score changes from baseline to week 24 on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog), a modified 20-item Activities of Daily Living Scale (ADL), the Neuropsychiatric Inventory (NPI), and the Mini-Mental State Examination (MMSE) as well as the score of the Clinician's Interview-Based Impression of Change plus Caregiver Input (CIBIC-Plus). RESULTS:One hundred sixty-seven AD patients with an MMSE score of 10-24 were analyzed. No significant differences in the score changes from baseline to week 24 on all outcomes or the four subscales of the ADAS-cog were observed between the two treatment groups. Donepezil resulted in an improved score for naming ability on the ADAS-cog compared to memantine (p = 0.036), whereas memantine more effectively reduced agitation as measured by the NPI compared to donepezil (p = 0.039). CONCLUSION: These findings support the efficacy of memantine for the treatment of mild-to-moderate AD, especially in patients with agitation.
RCT Entities:
BACKGROUND/AIMS: Memantine has been approved by the Food and Drug Administration for the treatment of moderate-to-severe Alzheimer's disease (AD). However, the effect of memantine on patients with mild-to-moderate AD is unclear. METHODS: This study is a post hoc analysis of a double-blind clinical trial. Donepezil was used as the standard control treatment. Outcomes included score changes from baseline to week 24 on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog), a modified 20-item Activities of Daily Living Scale (ADL), the Neuropsychiatric Inventory (NPI), and the Mini-Mental State Examination (MMSE) as well as the score of the Clinician's Interview-Based Impression of Change plus Caregiver Input (CIBIC-Plus). RESULTS: One hundred sixty-seven ADpatients with an MMSE score of 10-24 were analyzed. No significant differences in the score changes from baseline to week 24 on all outcomes or the four subscales of the ADAS-cog were observed between the two treatment groups. Donepezil resulted in an improved score for naming ability on the ADAS-cog compared to memantine (p = 0.036), whereas memantine more effectively reduced agitation as measured by the NPI compared to donepezil (p = 0.039). CONCLUSION: These findings support the efficacy of memantine for the treatment of mild-to-moderate AD, especially in patients with agitation.
Authors: Prasad R Padala; Kalpana P Padala; Shelly Y Lensing; Andrea N Jackson; Cassandra R Hunter; Christopher M Parkes; Richard A Dennis; Melinda M Bopp; Ricardo Caceda; Mark S Mennemeier; Paula K Roberson; Dennis H Sullivan Journal: Psychiatry Res Date: 2018-01-05 Impact factor: 3.222
Authors: Anita E Saltmarche; Margaret A Naeser; Kai Fai Ho; Michael R Hamblin; Lew Lim Journal: Photomed Laser Surg Date: 2017-02-10 Impact factor: 2.796